Company & Sponsor Intelligence

Brown University

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials4

Recruiting0

Completed3

Countries1

Therapeutic footprint

anxietydepressionparkinsonsschizophrenia

Indexed studies

NCT01214005Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls
schizophrenia · United StatesPHASE2

NCT01382342The Effect of Rasagiline on Cognition in Parkinson's Disease
parkinsons · United StatesPHASE4

NCT01831362Dismantling Mindfulness: Contributions of Attention vs. Acceptance
depression · United StatesNA

NCT06051084Investigating How the Brain Processes Different Experiences
anxiety · United StatesNA

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →